Transcatheter Mitral Valve Repair

Transcatheter mitral valve repair in addition to medical therapy led to a lower rate of CV events and hospitalizations and better health status compared with medical therapy alone for patients with HF and moderate to severe mitral regurgitation.

SAN FRANCISCO — Data show a novel transcatheter mitral valve edge-to-edge repair system was associated with a sustained reduction in mitral regurgitation plus functional and quality-of-life gains for patients at prohibitive surgical risk.

SAN FRANCISCO — A fourth-generation mitral valve transcatheter edge-to-edge repair system was associated with durable reduction in mitral regurgitation severity to mild or less for most patients, including those with complex anatomy.

A transapical transcatheter mitral valve repair system was linked to extensive reduction in mitral regurgitation at 2 years in patients ineligible for surgery, researchers reported at TVT: The Structural Heart Summit.

In patients with HF and severe secondary mitral regurgitation, transcatheter edge-to-edge mitral valve repair reduced mortality and HF hospitalization regardless of whether patients had malnutrition, new data from the COAPT trial show.

In patients with HF undergoing mitral valve transcatheter edge-to-edge repair, a novel staging classification of valve disease based on extravalvular cardiac damage may improve symptomatic outcomes and survival, researchers reported.

Transcatheter Cardiovascular Therapeutics, held Sept. 16 to 19 in Boston, featured the latest clinical science in interventional cardiology, as well as forums on innovative technologies, regulatory matters and other topics.

A novel risk score comprising clinical, echocardiographic and treatment variables accurately predicted prognosis for adults with HF and severe secondary mitral regurgitation after transcatheter mitral valve repair, researchers reported.

BOSTON — In this Healio video exclusive, B. Hadley Wilson, MD, FACC, discussed late-breaking research in transcatheter aortic valve replacement, and more presented at TCT 2022.

Edwards Lifesciences announced its precision transcatheter mitral valve repair system for edge-to-edge repair received FDA approval for the treatment of degenerative mitral regurgitation.